Why Aphria Inc. Is My Least Favourite TSX-Traded Marijuana Stock

Why Aphria Inc. (TSX:APH) may be the riskiest of the risky Canadian marijuana stocks. Here’s what you need to know before you jump in head first.

| More on:

I’m not a fan of Aphria Inc. (TSX:APH) despite its clear industry-leading fundamentals in the early stages of the nascent marijuana industry. Although Aphria has received praise from fellow Fool contributors Chris MacDonald and Jason Phillips for being a low-cost operator with above-average fundamentals versus industry averages, I’m very paranoid about the negative implications from Aphria’s U.S. assets.

As you may be aware, Aphria’s U.S. assets are technically considered illegal, as cannabis is still not decriminalized at the federal level. Because Aphria isn’t complying with U.S. law, many investors are worried that the stock could suddenly become delisted from the TSX. Although Aphria CEO Vic Neufeld is committed to protecting Aphria’s shareholders, I believe the potential for a rushed U.S. asset liquidation may end up destroying value for longer-term shareholders.

I also believe that Neufeld is downplaying their concerns. The potential implications may be more insidious than what the general public is expecting, so I’d advise caution for those who favour Aphria as their top marijuana pick.

Nobody really knows how long Aphria has to get rid of its U.S. assets in order to fully comply with U.S. law. And even if we did, it’s likely that Aphria could dispose of its U.S. assets for next to nothing!

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was in a similar predicament as it entered divestiture mode over a year ago; however, Aphria’s timeframe for such divestments is likely a lot shorter than that of Valeant’s.

Valeant was scrambling to pay back its debt obligations, and Aphria is in a divestiture rush in order to comply with standards that’ll allow its stock to continue to be traded on the TSX exchange. As of right now, there’s very little visibility. If I were an investor, that would make me really paranoid! What are the real implications of a TSX delisting? How long does Aphria actually have to get rid of its U.S. assets? Is there a workaround? Are investors in any danger?

These are all questions that give rise to another layer of uncertainty that appears to be unique to Aphria when you consider the big four TSX-traded marijuana producers.

The solution is simple. Just buy one of the other three Canadian producers in Canopy Growth Corp. (TSX:WEED), Aurora Cannabis Inc. (TSX:ACB) or MedReleaf Corp. (TSX:LEAF). Why anyone would want an extra layer of uncertainty in an already uncertain and speculative industry is anyone’s guess. I think Aphria investors are either too hopeful or they’re too high on Aphria’s exceptional fundamentals, which really stand out.

Personally, I think the superior fundamentals mean very little at this stage. While Aphria’s management team has done an impeccable job thus far, I believe the potential for a delistment outweighs the benefits of the company’s top-notch fundamentals in the early stages of an evolving industry.

Bottom line

For branding and longer-term prospects, I prefer Canopy and MedReleaf for the recreational and medical markets, respectively. And for nearer-term catalysts, I prefer Aurora. Right now, Aphria has a huge headwind that’s just another added risk in an already dangerously risky industry.

Also, a word of warning.

Although I’m a fan of the growth prospects behind cannabis producers, I’m not at all a fan of the valuations after the exponential run-up. At these prices, it looks like you’re paying up for two or even three years’ worth of growth. The valuations are ridiculous, and I wouldn’t recommend owning any cannabis stocks until the industry experiences a correction, which I believe it will this year.  So be patient and make sure you have cash on hand.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Aircraft wing plane

Prediction: Air Canada Stock Will Sit on the Runway for a While

Will Air Canada stock be able to continue to ride post-pandemic tailwinds, or is this stock pricing in an upcoming…

Read more »

Businessman holding AI cloud
Tech Stocks

Artificial Intelligence, Real Returns: Profiting From the AI Revolution

Tech companies like Shopify Inc (TSX:SHOP) are profiting from the AI revolution.

Read more »

Paper airplanes flying on blue sky with form of growing graph

Are Airline Stocks a Good Buy in December 2023?

Airline stocks are cyclical. So, interested investors should aim to buy low and sell high to target price appreciation.

Read more »

little girl in pilot costume playing and dreaming of flying over the sky
Stocks for Beginners

TFSA Investors: 3 Steps to Get Into Cross-Border Investing

Overseas trading can be scary. But if you follow these steps, you can certainly achieve far higher returns than just…

Read more »

Dividend Stocks

2 Top Telecommunication Stocks to Buy on the TSX Today

Two telco stocks, but not the dominant industry players, are buying opportunities on the TSX today.

Read more »

Business man on stock market financial trade indicator background.

Better Buy: Canadian Bank Stocks or Fintech Stocks?

Bank stocks like Bank of Nova Scotia (TSX:BNS) are often cheaper than fintech stocks.

Read more »

worry concern
Dividend Stocks

Is Now Actually the Right Time to Buy BCE Stock?

Looking for a great stock to buy at a serious discount? It’s the right time to buy BCE (TSX:BCE) stock…

Read more »

Illustration of bull and bear
Dividend Stocks

Defensive Sectors: A Safe Haven for Canadian Investors in a Bear Market       

As uncertainty continues to increase in the stock market, buying stocks in defensive sectors can help protect your capital.

Read more »